SCHEMBL2233937

SCHEMBL2233937

CCCCCCCCCCCCCCCCOC[C@H](COC(c1ccccc1)(c1ccccc1)c1ccccc1)O[C@H](COCCCCCCCCCCCCCCCC)COC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 2/20 0.47
PLA2G10 O15496 1/20 0.47
PLA2G1B P04054 1/20 0.47
PLA2G5 P39877 1/20 0.47
KIF11 P52732 1/20 0.39
USP2 O75604 1/20 0.37
HTT P42858 1/20 0.36
LTA4H P09960 1/20 0.36
PRKD3 O94806 1/20 0.36
PRKCG P05129 1/20 0.36
PRKCB P05771 1/20 0.36
PRKCA P17252 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCI P41743 1/20 0.36
PRKCE Q02156 1/20 0.36
PRKCQ Q04759 1/20 0.36
PRKCZ Q05513 1/20 0.36
PRKCD Q05655 1/20 0.36
PRKD1 Q15139 1/20 0.36
TK2 O00142 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6700873 0.90 PRKD3 (0.48) PLA2G2APLA2G10PLA2G1BPLA2G5KIF11
SCHEMBL8917115 0.90 PLA2G2A (0.56) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL497520 0.90 PLA2G2A (0.56) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL9137670 0.90 PLA2G2A (0.56) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL8638519 0.90 PRKD3 (0.48) PLA2G2APLA2G10PLA2G1BPLA2G5KIF11
SCHEMBL8979451 0.89 PLA2G2A (0.54) PLA2G2APLA2G10PLA2G1BPLA2G5KIF11
SCHEMBL25763996 0.85 PLA2G2A (0.48) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL8357825 0.85 PLA2G2A (0.59) PLA2G2APLA2G10PLA2G1BPLA2G5KIF11
SCHEMBL25243275 0.84 USP2 (0.50) PLA2G2APLA2G10PLA2G1BPLA2G5KIF11
SCHEMBL10706918 0.84 PLA2G2A (0.41) PLA2G2APLA2G10PLA2G1BPLA2G5KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B PLA2G2A 343/4885PLA2G10 397/4885PLA2G1B 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.